Skip to main content
padlock icon - secure page this page is secure

Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease

Buy Article:

$52.00 + tax (Refund Policy)

Summary objective 

To determine baseline characteristics and the effects of 2 years of GH replacement therapy on body composition, muscle strength, bone mass, and metabolic indices in GH-deficient (GHD) adults previously treated for pituitary-dependent Cushing's disease. design 

A single-centre, open-labelled, prospective study. patients 

Fifteen consecutive GHD adults previously treated for pituitary-dependent Cushing's disease (CD group) and 15 closely matched GHD adults with previous nonfunctioning hypopituitary disease (NF group) were included. All patients had adult-onset GH deficiency. results 

The mean dose of GH was similar in both study groups during the 2-year treatment. At baseline, diastolic blood pressure was higher, and lumbar (L2–L4) bone mineral density (BMD) was lower, in the CD group than in the NF group. The increase in lean mass in response to GH therapy, as measured by dual-energy X-ray absorptiometry (DEXA), was less marked in the CD group. GH replacement therapy reduced diastolic blood pressure only in the CD group. The patients in the CD group had greater treatment response in lumbar (L2–L4) spine BMD and in isometric and isokinetic knee extension strength than the patients in the NF group. At study end, no difference remained between the two study groups. conclusions 

This study revealed differences in the baseline characteristics between GHD patients previously treated for Cushing's disease as compared with closely matched GHD patients with previous nonfunctioning hypopituitary disease. The 2-year GH replacement therapy eliminated all the differences between the two study groups.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Affiliations: 1: Research Centre for Endocrinology and Metabolism and 2: Rehabilitation Medicine, Institute of Clinical Neuroscience, Sahlgrenska University Hospital, Göteborg, Sweden

Publication date: May 1, 2004

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more